• GoHealth Reports Fourth Quarter and Fiscal 2023 Results

    Источник: Nasdaq GlobeNewswire / 14 мар 2024 06:00:01   America/New_York

    CHICAGO, March 14, 2024 (GLOBE NEWSWIRE) -- GoHealth, Inc. (NASDAQ: GOCO) (“GoHealth” or the “Company”), a leading health insurance marketplace and Medicare-focused digital health company, today announced unaudited financial results for the fourth quarter and year ended December 31, 2023.

    • The Company generated $109.1 million of cash flow from operations in 2023, a substantial 79.2% improvement compared to $60.9 million in the prior year period.
    • The percentage of revenue earned from non-agency sales in the fourth quarter was 60% of Medicare revenue, compared to 26% in 2022. This shift to non-agency operating model continues to drive cash generation.
    • Fourth quarter 2023 net revenues were $276.7 million, compared to $69.4 million in the prior year period. Full year 2023 net revenues were $734.7 million, compared to $631.7 million in 2022.
    • Fourth quarter 2023 net loss was $2.3 million and Adjusted EBITDA1 was $57.0 million, improvements of 98.5% and 160.1%, respectively, compared to the prior year period. Full year 2023 net loss of $151.3 million and Adjusted EBITDA1 of $75.1 million were improvements of 59.8% and 157.9%, respectively, compared to the prior year period.
    • As a result of the improved performance of the Company and focus on higher quality submissions, there was no Lookback adjustment recorded in 2023. The Company recorded lookback adjustments in 2022 that are detailed in the tables below.
    • GoHealth assisted over two million Medicare consumers assess their benefit options in 2023.

    "As we reflect on our achievements this past year, our consumer-centric focus shifted from enrollment to engagement, with trust at its core. Our innovative PlanFit CheckUp program is a prime example of our commitment to the consumer and a driver of our 2023 results. By prioritizing the real needs of Medicare consumers, we continue to enhance consumer trust and set a new standard for industry practices, said Vijay Kotte, CEO of GoHealth. “Our approach underscores our mission to transform the consumer healthcare journey, ensuring every action we take is aligned with our core values of transparency, trust, and integrity,” continued Kotte.

    “In 2023, GoHealth did right by the consumer while staying true to our values as a company and effectively managing our cash. Our results showcase a meaningful year over year increase in profitability and significant improvement in our operating cash flow, highlighting the effectiveness of our strategic initiatives and the unwavering commitment of our team," said Jason Schulz, CFO of GoHealth.

    (1) Adjusted EBITDA is a non-GAAP measure. For a definition of Adjusted EBITDA and a reconciliation to the most comparable GAAP measure, please see below.

    Conference Call Details

    The Company will host a conference call today, Thursday, March 14, 2024 at 8:00 a.m. (ET) to discuss its financial results. Participants can pre-register for the conference call at the following link: Webcast Pre-registration. A live audio webcast of the conference call will be available via GoHealth's Investor Relations website, https://investors.gohealth.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call.

    About GoHealth, Inc.:

    GoHealth is a leading health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers’ peace of mind when making healthcare decisions so they can focus on living life. For many of these consumers, enrolling in a health insurance plan is confusing and difficult, and seemingly small differences between health plans may lead to significant out-of-pocket costs or lack of access to critical providers and medicines. GoHealth’s proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer’s specific needs. Its unbiased, technology-driven marketplace coupled with highly skilled licensed agents has facilitated the enrollment of millions of consumers in Medicare plans since GoHealth’s inception. For more information, visit https://www.gohealth.com.

    Investor Relations:
    John Shave
    JShave@gohealth.com

    Media Relations:
    Pressinquiries@gohealth.com

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are made in reliance upon the safe harbor provision of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Statements regarding our future results of operations and financial position, business strategy and plans and objectives of management for future operations, including, among others, statements regarding our expected growth, future capital expenditures and debt service obligations are forward-looking statements.

    In some cases, you can identify forward-looking statements by terms, such as “may,” “will,” “should,” “aim,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” “likely,” “strive”, “future,” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions, projections and other statements about future events that are based on current expectations and assumptions. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.

    These forward-looking statements speak only as of the date of this press release and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including, but not limited to the following: the marketing and sale of Medicare plans are subject to numerous, complex and frequently changing laws, regulations and guidelines; our operating results have been, and may continue to be, adversely impacted by factors that impact our estimate of LTV (as defined below); our gradual expansion of the Encompass Solution may not be as successful as we expect; our business may be harmed if we lose our relationships with health plan partners or if our relationships with health plan partners change; health plan partners may reduce the commissions paid to us and change their underwriting practices in ways that reduce the number of, or impact the renewal or approval rates of, insurance policies sold through our platform; we currently depend on a small group of health plan partners for a substantial portion of our revenue and losing our relationships with any of these health plan partners may disproportionately impact our financial position and performance; changes and developments in the health insurance system and laws and regulations governing the health insurance markets in the United States could materially adversely affect our business, operating results, financial condition and qualified prospects; we rely on certain services from the Centers for Medicare & Medicaid Services, and a federal government shutdown that impedes our ability to use these services may materially impact our business; information technology system failures could interrupt our operations; volatility in general economic conditions, including inflation, interest rates, and commodity prices and exchange rates may impact our financial position and performance; we may lose key employees or fail to attract qualified employees; our failure to grow our customer base or retain our existing customers; we may not realize the benefits we expect from our strategic cash flow optimization and other cash management initiatives; our ability to sell Medicare-related health insurance plans is largely dependent on our licensed health insurance agents; operating and growing our business may require additional capital; and the Founders and Centerbridge have significant influence over us, including control over decisions that require the approval of stockholders.

    The foregoing factors should not be construed as exhaustive and should be read together with the other cautionary statements included in this press release, as well as the cautionary statements and other risk factors set forth in the Company’s 2022 Annual Report on Form 10-K, Quarterly Report on Form 10-Q for the first quarter ended March 31, 2023, Quarterly Report on Form 10-Q for the second quarter ended June 30, 2023, Quarterly Report on Form 10-Q for the third quarter ended September 30, 2023, the forthcoming 2023 Annual Report on Form 10-K and other SEC filings. If one or more events related to these or other risks or uncertainties materialize, or our underlying assumptions prove to be incorrect, actual results may differ materially from what we anticipate. Many of the important factors that will determine these results are beyond our ability to control or predict. Accordingly, you should not place undue reliance on any such forward-looking statements. Any forward-looking statement speaks only as of the date on which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time to time, and it is not possible for us to predict which will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

    Use of Non-GAAP Financial Measures and Key Performance Indicators

    In this press release, we use supplemental measures of our performance that are derived from our consolidated financial information, but which are not presented in our Consolidated Financial Statements prepared in accordance with GAAP. These non-GAAP financial measures include net income (loss) before interest expense, income tax (benefit) expense and depreciation and amortization expense, or EBITDA; Adjusted EBITDA; Adjusted EBITDA margin; Sales per Submission; Cost per Submission and Adjusted Gross Margin per Submission. Adjusted EBITDA is the primary financial performance measure used by management to evaluate the business and monitor its results of operations. Sales per Submission, Cost per Submission and Adjusted Gross Margin per Submission are key operating metrics used by management to understand the Company’s underlying financial performance and trends.

    Additional non-GAAP financial measures, including net revenue excluding the Lookback Adjustments, Adjusted EBITDA excluding the Lookback Adjustments, net revenue excluding both the Non-Encompass BPO Services revenue and the Lookback Adjustments and Adjusted EBITDA excluding both the Non-Encompass BPO Services gross margin and the Lookback Adjustments, are also discussed in this press release. The Lookback Adjustments are revenue adjustments that represent changes in estimates relating to performance obligations satisfied in prior periods and relate to the fiscal years 2021 and prior.

    Adjusted EBITDA represents, as applicable for the period, EBITDA as further adjusted for certain items summarized below in this press release. Adjusted EBITDA margin represents Adjusted EBITDA divided by net revenues. Sales per Submission represents Medicare Revenue per Submission as further adjusted for certain items summarized below in this press release. Cost per Submission represents Operating Expense per Submission as further adjusted for certain items summarized below in this press release. Adjusted Gross Margin represents Sales per Submission less Cost per Submission.

    We use non-GAAP financial measures to supplement financial information presented on a GAAP basis. We believe that excluding certain items from our GAAP results allows management to better understand our consolidated financial performance from period to period and better project our future consolidated financial performance as forecasts are developed at a level of detail different from that used to prepare GAAP-based financial measures. Moreover, we believe these non-GAAP financial measures provide our stakeholders with useful information to help them evaluate our operating results by facilitating an enhanced understanding of our operating performance and enabling them to make more meaningful period to period comparisons. Adjusted EBITDA is used as a basis for certain compensation programs sponsored by the Company. There are limitations to the use of the non-GAAP financial measures presented in this press release. For example, our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

    The non-GAAP financial measures are not meant to be considered as indicators of performance in isolation from or as a substitute for the most directly comparable measures prepared in accordance with GAAP, and should be read only in conjunction with financial information presented on a GAAP basis. Reconciliations of each of EBITDA, Adjusted EBITDA, net revenue excluding the Lookback Adjustments, Adjusted EBITDA excluding the Lookback Adjustments, net revenue excluding both the Non-Encompass BPO Services revenue and the Lookback Adjustments, Adjusted EBITDA excluding both the Non-Encompass BPO Services gross margin and the Lookback Adjustments, Sales per Submission, Cost per Submission and Adjusted Gross Margin per Submission to its most directly comparable GAAP financial measure, are presented in the tables below in this press release. We encourage you to review the reconciliations in conjunction with the presentation of the non-GAAP financial measures for each of the periods presented. In future periods, we may exclude similar items, may incur income and expenses similar to these excluded items and include other expenses, costs and non-recurring items.

    The Company is unable to provide a full reconciliation of guidance for Adjusted EBITDA without unreasonable effort because it is not possible to predict certain adjustment items with a reasonable degree of certainty since they are not yet known or quantifiable, and do not relate to the Company’s routine activities. This information is dependent upon future events, which may be outside of the Company’s control and could have a significant impact on its GAAP financial results for fiscal year 2023.

    Glossary

    • “Adjusted EBITDA” represents, as applicable for the period, EBITDA as further adjusted for certain items summarized below in this press release.
    • “Adjusted EBITDA Margin” refers to Adjusted EBITDA divided by net revenues.
    • “Adjusted Gross Margin per Submission” refers to Sales per Submission less Cost per Submission.
    • “Cash Adjusted EBITDA” refers to Adjusted EBITDA plus a decrease or less an increase in the year over year change in our net contract asset.
    • “Cost of Submission” refers to the aggregate cost to convert prospects into Submissions during a particular period. Cost of Submission is comprised of revenue share, marketing and advertising expenses and customer care and enrollment expenses, excluding share-based compensation expense, the impact of revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods and such expenses related to Non-Encompass BPO Services.
    • “Cost per Submission” refers to (x) the aggregate cost to convert prospects into Submissions for a particular period (comprised of revenue share, marketing and advertising expenses, and customer care and enrollment expenses, excluding share-based compensation expense and such expenses related to Non-Encompass BPO Services) divided by (y) number of Submissions.
    • “EBITDA” represents net income (loss) before interest expense, income tax expense (benefit) and depreciation and amortization expense.
    • “Gross margin” refers to net revenue divided by revenue share, marketing and advertising expenses and customer care and enrollment expenses.
    • “Lookback Adjustment” refers to negative revenue adjustments that represent changes in estimates relating to performance obligations satisfied in prior periods
    • “LTV” refers to the Lifetime Value of Commissions, which we define as aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints.
    • “Non-Encompass BPO Services” refer to programs in which GoHealth-employed agents are dedicated to certain health plan partners and agencies we partner with outside of the Encompass operating model.
    • “Sales per Submission” refers to (x) the sum of (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, (ii) non-agency revenue, and (iii) partner marketing and other revenue, divided by (y) the number of Submissions for such period.
    • “Sales/Cost of Submission” refers to (x) the sum of (i) aggregate commissions estimated to be collected over the estimated life of all commissionable Submissions for the relevant period based on multiple factors, including but not limited to, contracted commission rates, health plan partner mix and expected policy persistency with applied constraints, excluding revenue adjustments recorded in the period, but relating to performance obligations satisfied in prior periods, (ii) non-agency revenue and (iii) partner marketing and other revenue, divided by (y) the aggregate cost to convert prospects into Submissions (comprised of revenue share, marketing and advertising expenses, and customer care and enrollment expenses, excluding share-based compensation expense) for such period. Sales/Cost of Submission exclude amounts related to Non-Encompass BPO Services.
    • “Submission” refers to either (i) a completed application with our licensed agent that is submitted to the health plan partner and subsequently approved by the health plan partner during the indicated period, excluding applications through our Non-Encompass BPO Services or (ii) a transfer by our agent to the health plan partner through the Encompass operating model during the indicated period.

    The following tables set forth the components of our results of operations for the periods indicated (unaudited):

      Three months ended Dec. 31,    
    (in thousands, except percentages and per share amounts)
    		  2023   2022     
     Dollars % of Net Revenues Dollars % of Net Revenues $ Change % Change
    Net revenues  276,697  100.0%  69,376  100.0%  207,321  298.8%
    Operating expenses:            
    Revenue share  41,085  14.8%  20,629  29.7%  20,456  99.2%
    Marketing and advertising expense  80,614  29.1%  56,151  80.9%  24,463  43.6%
    Customer care and enrollment  75,199  27.2%  64,752  93.3%  10,447  16.1%
    Technology expense  11,596  4.2%  11,525  16.6%  71  0.6%
    General and administrative  19,629  7.1%  25,671  37.0%  (6,042) (23.5)%
    Amortization of intangible assets  23,514  8.5%  23,514  33.9%  —  —%
    Goodwill and intangible asset impairment charges  10,000   3.6%  —   —%  10,000  NM 
    Restructuring and other related charges  —  —%  312  0.4%  (312) (100.0)%
    Total operating expenses  261,637  94.6%  202,554  292.0%  59,083  29.2%
    Income (loss) from operations  15,060  5.4%  (133,178) (192.0)%  148,238  (111.3)%
    Interest expense  17,751  6.4%  17,317  25.0%  434  2.5%
    Other (income) expense, net  (776) (0.3)%  (50) (0.1)%  (726) 1,452.0%
    Income (loss) before income taxes  (1,915) (0.7)%  (150,445) (216.9)%  148,530  (98.7)%
    Income tax expense (benefit)  379  0.1%  292  0.4%  87  29.8%
    Net income (loss) $(2,294) (0.8)% $(150,737) (217.3)% $148,443  (98.5)%
    Net income (loss) attributable to noncontrolling interests  (1,068) (0.4)%  (89,338) (128.8)%  88,270  (98.8)%
    Net income (loss) attributable to GoHealth, Inc. $(1,226) (0.4)% $(61,399) (88.5)% $60,173  (98.0)%
    Net income (loss) per share:            
    Net income (loss) per share of common stock — basic and diluted $(0.22)   $(7.00)      
    Weighted-average shares of Class A common stock outstanding —basic and diluted  9,582     8,895       
    Non-GAAP financial measures:            
    EBITDA $42,684    $(106,550)      
    Adjusted EBITDA $57,000    $(94,781)      
    Adjusted EBITDA margin  20.6%   (136.6)%      


      Twelve months ended Dec. 31,    
    (in thousands, except percentages and per share amounts)
    		  2023   2022     
     Dollars % of Net Revenues Dollars % of Net Revenues $ Change % Change
    Net revenues  734,671  100.0%  631,675  100.0%  102,996  16.3%
    Operating expenses:            
    Revenue share  158,961  21.6%  187,670  29.7%  (28,709) (15.3)%
    Marketing and advertising expense  205,042  27.9%  207,559  32.9%  (2,517) (1.2)%
    Customer care and enrollment  209,234  28.5%  260,902  41.3%  (51,668) (19.8)%
    Technology expense  43,302  5.9%  46,094  7.3%  (2,792) (6.1)%
    General and administrative  93,069  12.7%  116,530  18.4%  (23,461) (20.1)%
    Amortization of intangible assets  94,057  12.8%  94,057  14.9%  —  —%
    Operating lease impairment charges  2,687  0.4%  25,345  4.0%  (22,658) (89.4)%
    Goodwill and intangible asset impairment charges  10,000  1.4%  —  —%  10,000  NM 
    Restructuring and other related charges  —  —%  12,184  1.9%  (12,184) NM 
    Total operating expenses  816,352  111.1%  950,341  150.4%  (133,989) (14.1)%
    Income (loss) from operations  (81,681) (11.1)%  (318,666) (50.4)%  236,985  (74.4)%
    Interest expense  69,472  9.5%  57,069  9.0%  12,403  21.7%
    Other (income) expense, net  (37) —%  (115) —%  78  (67.8)%
    Income (loss) before income taxes  (151,116) (20.6)%  (375,620) (59.5)%  224,504  (59.8)%
    Income tax expense (benefit)  154  —%  764  0.1%  (610) (79.8)%
    Net income (loss) $(151,270) (20.6)% $(376,384) (59.6)% $225,114  (59.8)%
    Net income (loss) attributable to noncontrolling interests  (88,013) (12.0)%  (227,678) (36.0)% $139,665  (61.3)%
    Net income (loss) attributable to GoHealth, Inc. $(63,257) (8.6)% $(148,706) (23.5)% $85,449  (57.5)%
    Net income (loss) per share:            
    Net income (loss) per share of common stock — basic and diluted $(7.19)   $(17.72)      
    Weighted-average shares of Class A common stock outstanding — basic and diluted  9,292     8,445       
    Non-GAAP financial measures:            
    EBITDA $24,104    $(211,549)      
    Adjusted EBITDA $75,091    $(129,776)      
    Adjusted EBITDA margin  10.2%   (20.5)%      

    _________________________
    NM = Not meaningful

    The following table sets forth the reconciliations of GAAP net income (loss) to EBITDA and Adjusted EBITDA for the periods indicated (unaudited):

      Three months ended Dec. 31, Twelve months ended Dec. 31,
    (in thousands)  2023   2022   2023   2022 
    Net revenues $276,697  $69,376  $734,671  $631,675 
    Net income (loss)  (2,294)  (150,737)  (151,270)  (376,384)
    Interest expense  17,751   17,317   69,472   57,069 
    Income tax expense (benefit)  379   292   154   764 
    Depreciation and amortization expense  26,848   26,578   105,748   107,002 
    EBITDA  42,684   (106,550)  24,104   (211,549)
    Goodwill and intangible asset impairment charges(1)  10,000   —   10,000   — 
    Share-based compensation expense (benefit)(2)  3,405   6,256   19,564   32,124 
    Professional services(3)  335   773   1,548   4,752 
    Other (income) loss related to the adjustment of liabilities under the Tax Receivable Agreement(4)  428   550   428   550 
    Legal fees(5)  148   3,478   14,840   3,478 
    Operating lease impairment charges(6)  —   —   2,687   25,345 
    Severance costs(7)  —   400   1,920   3,340 
    Restructuring and other related charges(8)  —   312   —   12,184 
    Adjusted EBITDA $57,000  $(94,781) $75,091  $(129,776)
    Adjusted EBITDA margin  20.6% (136.6)%  10.2% (20.5)%

    _________________________
    (1) Represents indefinite-lived intangible asset impairment charges for the twelve months ended December 31, 2023
    (2) Represents non-cash share-based compensation expense (benefit) relating to equity awards as well as share-based compensation expense (benefit) relating to liability classified awards that will be settled in cash.
    (3) Represents costs primarily associated with non-recurring consulting fees and other professional services.
    (4) Represents expense related to the measurement of our Tax Receivable Agreement obligation.
    (5) Represents non-routine legal fees, settlement accruals and other expenses unrelated to our corporate operations.
    (6) Represents operating lease impairment charges, reducing the carrying value of the associated ROU assets and leasehold improvements to the estimated fair values.
    (7) Represents costs associated with the termination of executive employment and associated fees unrelated to restructuring activities.
    (8) Represents employee termination benefits and other associated costs related to restructuring activities.

    The following table summarizes net revenues and Adjusted EBITDA excluding the Lookback Adjustments and Non-Encompass BPO Services for the periods indicated (unaudited):

      Three months ended Dec. 31, Twelve months ended Dec. 31,
    (in thousands)  2023   2022   2023   2022 
    Net revenues $276,697  $69,376  $734,671  $631,675 
    Lookback Adjustments reported during the indicated periods  —   266,383   —   275,709 
    Net revenue excluding Lookback Adjustments  276,697   335,759   734,671   907,384 
    Exit of non-Encompass BPO Services  (155)  (34,198)  (9,477)  (110,865)
    Net revenues excluding Lookback Adjustments and non-Encompass BPO Services  276,542   301,561   725,194   796,519 
             
    Adjusted EBITDA $57,000  $(94,781) $75,091  $(129,776)
    Lookback Adjustments reported during the indicated periods  —   186,617   —   192,693 
    Adjusted EBITDA excluding Lookback Adjustments  57,000   91,836   75,091   62,917 
    Exit of non-Encompass BPO Services  (147)  (6,980)  (2,665)  (20,476)
    Adjusted EBITDA excluding Lookback Adjustments and non-Encompass BPO Services $56,853  $84,856  $72,426  $42,441 
    Adjusted EBITDA margin excluding Lookback Adjustments and non-Encompass BPO Services  20.6%  28.1%  10.0%  5.3%


    The following table sets forth the reconciliations of Adjusted EBITDA to Cash Adjusted EBITDA for the periods indicated (unaudited):

      Twelve months ended Dec. 31,
    (in thousands)  2023   2022   2021 
    Adjusted EBITDA $75,091  $(129,776) $33,821 
    Beginning commissions receivable  1,031,433   1,262,507   810,398 
    Beginning commissions payable  (375,141)  (378,563)   (261,074) 
    Beginning net contract assets  656,292   883,944   549,324 
    Ending commissions receivable  911,697   1,031,433   1,262,507 
    Ending commissions payable  (321,987)  (375,141)   (378,563) 
    Ending net contract assets  589,710   656,292   883,944 
    (Increase)/decrease in contract asset  66,582   227,652   (334,620)
    Cash Adjusted EBITDA $141,673  $97,876  $(300,799)


    The following table summarizes share-based compensation expense (benefit) by operating function for the periods indicated (unaudited):

      Three months ended Dec. 31, Twelve months ended Dec. 31,
    (in thousands)  2023   2022  2023  2022
    Marketing and advertising  (50)  490 $328 $1,653
    Customer care and enrollment  460   484  2,307  2,218
    Technology  635   471  3,000  2,924
    General and administrative  2,360   4,811  13,929  25,329
    Total share-based compensation expense (benefit) $3,405  $6,256 $19,564 $32,124


    The table below depicts the disaggregation of revenue and is consistent with how the Company evaluates its financial performance (unaudited):

      Three months ended Dec. 31, Twelve months ended Dec. 31,
    (in thousands)  2023  2022   2023  2022
    Medicare Revenue        
    Agency Revenue        
    Commission Revenue(1) $94,405 $(66,294) $355,918 $316,734
    Partner Marketing and Other Revenue  16,093  37,852   87,712  112,983
    Total Agency Revenue  110,498  (28,442)  443,630  429,717
    Non-Agency Revenue  165,383  85,185   271,969  107,336
    Total Medicare Revenue  275,881  56,743   715,599  537,053
    Other Revenue        
    Non-Encompass BPO Services Revenue  —  11,870   9,322  87,383
    Other Revenue  816  763   9,750  7,239
    Total Other Revenue  816  12,633   19,072  94,622
    Total Net Revenue $276,697 $69,376  $734,671 $631,675

    (1) Commission revenue excludes commissions generated through the Company’s Non-Encompass BPO Services as well as from the sale of individual and family plan insurance products.

    The following table sets forth our balance sheets for the periods indicated (unaudited):

      Dec. 31,
    (in thousands, except per share amounts)  2023   2022 
    Assets    
    Current assets:    
    Cash and cash equivalents $90,809  $16,464 
    Accounts receivable, net of allowance for doubtful accounts of $27 in 2023 and $89 in 2022  250   4,703 
    Commissions receivable - current  336,215   335,796 
    Prepaid expense and other current assets  49,166   57,593 
    Total current assets  476,440   414,556 
    Commissions receivable - non-current  575,482   695,637 
    Operating lease ROU asset  21,995   21,483 
    Other long-term assets  2,256   1,721 
    Property, equipment, and capitalized software, net  26,843   25,282 
    Intangible assets, net  396,554   500,611 
    Total assets $1,499,570  $1,659,290 
    Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity    
    Current liabilities:    
    Accounts payable $17,705  $15,148 
    Accrued liabilities  86,254   53,334 
    Commissions payable - current  118,732   122,023 
    Short-term operating lease liability  5,797   8,974 
    Deferred revenue  52,403   50,594 
    Current portion of long-term debt  75,000   5,270 
    Other current liabilities  14,122   10,112 
    Total current liabilities  370,013   265,455 
    Non-current liabilities:    
    Commissions payable - non-current  203,255   253,118 
    Long-term operating lease liability  39,547   38,367 
    Long-term debt, net of current portion  422,705   504,810 
    Other non-current liabilities  9,095   5,839 
    Total non-current liabilities  674,602   802,134 
    Commitments and Contingencies    
    Series A redeemable convertible preferred stock — $0.0001 par value; 50 shares authorized; 50 shares issued and outstanding as of both December 31, 2023 and December 31, 2022. Liquidation preference of $50.9 million as of both December 31, 2023 and December 31, 2022.  49,302   49,302 
    Stockholders’ equity:    
    Class A common stock – $0.0001 par value; 1,100,000 shares authorized; 9,823 and 8,963 shares issued; 9,651 and 8,950 shares outstanding as of December 31, 2023 and December 31, 2022, respectively.  1   1 
    Class B common stock – $0.0001 par value; 616,018 shares authorized; 12,814 and 13,054 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively.  1   1 
    Preferred stock – $0.0001 par value; 20,000 shares authorized (including 50 shares of Series A redeemable convertible preferred stock authorized and 200 shares of Series A-1 convertible preferred stock authorized); 50 shares issued and outstanding as of both December 31, 2023 and December 31, 2022.  —   — 
    Series A-1 convertible preferred stock— $0.0001 par value; 200 shares authorized; no shares issued and outstanding as of both December 31, 2023 and December 31, 2022.  —   — 
    Treasury stock – at cost; 173 and 13 shares of Class A common stock as of December 31, 2023 and December 31, 2022, respectively.  (2,640)  (345)
    Additional paid-in capital  654,059   626,269 
    Accumulated other comprehensive income (loss)  (127)  (144)
    Accumulated deficit  (420,280)  (357,023)
    Total stockholders’ equity attributable to GoHealth, Inc.  231,014   268,759 
    Non-controlling interests  174,639   273,640 
    Total stockholders’ equity  405,653   542,399 
    Total liabilities, redeemable convertible preferred stock and stockholders’ equity $1,499,570  $1,659,290 


    The following table sets forth our statements of cash flows for the periods indicated (unaudited):

      Twelve months ended Dec. 31,
    (in thousands)  2023   2022 
    Operating Activities    
    Net income (loss) $(151,270) $(376,384)
    Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:    
    Share-based compensation  19,549   27,142 
    Depreciation and amortization  11,691   12,945 
    Amortization of intangible assets  94,057   94,057 
    Amortization of debt discount and issuance costs  3,196   2,896 
    Operating lease impairment charges  2,687   25,345 
    Non-cash restructuring charges  —   976 
    Non-cash lease expense  4,016   4,017 
    Other non-cash items, net  (902)  (250)
    Changes in assets and liabilities:    
    Accounts receivable  5,386   12,574 
    Commissions receivable  119,706   231,274 
    Prepaid expenses and other assets  7,512   2,140 
    Accounts payable  2,556   (24,795)
    Accrued liabilities  32,920   546 
    Deferred revenue  1,809   50,058 
    Commissions payable  (53,154)  (3,423)
    Operating lease liabilities  (8,731)  (6,597)
    Other liabilities  8,113   8,383 
    Net cash provided by (used in) operating activities  109,141   60,904 
    Investing Activities    
    Acquisition of business, net of cash    
    Purchases of property, equipment and capitalized software  (13,732)  (13,512)
    Net cash used in investing activities  (13,732)  (13,512)
    Financing Activities    
    Repayment of borrowings  (15,336)  (160,270)
    Proceeds from stock option exercises  91   5 
    Proceeds from sale of Series A redeemable convertible preferred stock  —   50,000 
    Issuance cost payments from issuance of Series A redeemable convertible preferred stock  —   (1,641)
    Debt issuance cost payments  —   (2,697)
    Repurchase of shares to satisfy employee tax withholding obligations  (2,295)  (345)
    Principal payments under capital lease obligations  —   (103)
    Net cash (used in) provided by financing activities  (21,106)  (115,051)
    Effect of exchange rate changes on cash and cash equivalents  42   (238)
    Increase (decrease) in cash and cash equivalents  74,345   (67,897)
    Cash and cash equivalents at beginning of period  16,464   84,361 
    Cash and cash equivalents at end of period $90,809  $16,464 
    Supplemental Disclosure of Cash Flow Information    
    Interest paid  55,345   56,920 
    Income taxes paid  548   486 
    Non-cash investing and financing activities:    
    Purchases of property, equipment and software included in accounts payable $2  $123 


    In addition to traditional financial metrics, we rely upon certain business and operating metrics to evaluate our business performance and facilitate our operations. Below are the most relevant business and operating metrics, for our single operating and reportable segment, except for EBITDA and Adjusted EBITDA.

    The following tables set forth the reconciliations of Medicare Revenue per Submission, Operating Expense per Submission and Gross Margin per Submission to Sales per Submission, Cost Per Submission, and Adjusted Gross Margin per Submission for the periods indicated (unaudited):

      Three months ended Dec. 31, Twelve months ended Dec. 31,
    (in thousands)  2023   2022   2023   2022 
    Sales per Submission        
    Medicare Revenue per Submission $957  $175  $866  $623 
    Lookback Adjustments reported during the indicated periods1  —   753
    		   —   292
    		 
    Sales per Submission $957  $928
    		  $866  $915
    		 
             
    Cost per Submission        
    Operating Expense per Submission $907  $625  $988  $1,102 
    Indirect operating expenses2  (218)  (188)  (292)  (341)
    Lookback Adjustments reported during the indicated periods1  —   188   —   73 
    Exit of Non-Encompass BPO Services  —   (27)  (10)  (82)
    Share-based compensation expense (benefit)3  (1)  (2)  (3)  (5)
    Cost per Submission $688  $596  $683  $747 
             
    Gross Margin per Submission4 $50  $(450) $(122) $(479)
    Adjusted Gross Margin per Submission5 $269  $332
    		  $183  $168
    		 

    (1) Excludes the impact of Lookback Adjustments on Non-Encompass BPO Services.
    (2) Indirect operating expenses include technology, general and administrative, amortization of intangible assets, operating lease impairment charges and restructuring and other related charges.
    (3) Share-based compensation expense included within marketing and advertising expenses and customer care and enrollment expenses.
    (4) Medicare Revenue per Submission less Operating Expense per Submission.
    (5) Sales per Submission less Cost per Submission.

    The following table presents the number of Submissions for the periods presented (unaudited):

     Three months ended Dec. 31,     
     2023 2022 Change % Change 
    Submissions288,127 324,133 (36,006) (11.1)%
           
    Twelve months ended Dec. 31,    
    2023 2022 Change % Change
     826,159 862,656 (36,497) (4.2)% 

    The following table presents the Sales per Submission (in thousands) for the period presented (unaudited):

     Three months ended Dec. 31,     
     2023 2022 $ Change % Change 
    Sales Per Submission$                       957 $                       928 $                         29 3.2%
           
    Twelve months ended Dec. 31,    
    2023 2022 $ Change % Change
     $                       866 $                       915 $                       (49) (5.3)%


    The following are our Sales/Cost of Submission, Cost of Submission (in thousands) and Cost Per Submission for the three and twelve months ended December 31, 2023 and 2022 (unaudited):

      Three months ended Dec. 31, Twelve months ended Dec. 31,
       2023  2022  2023  2022
    Sales/Cost of Submission  1.4  1.6  1.3  1.2
    Cost of Submission $197,940 $193,172 $563,552 $644,706
    Cost per Submission $688 $596 $683 $747

    Primary Logo

Опубликовать